Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022 Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data, potential payments upon option exercise and… Read More
December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with… Read More
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00 AM Eastern Daylight Time OSLO, Norway–(BUSINESS WIRE)–CEPI, the Coalition… Read More
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019 GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19… Read More
CHENGDU, China, London, UK – 24 February 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). GSK will provide Clover with its pandemic adjuvant… Read More
